Cytotheryx vs Eikon Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $60M Series A (Jan 2026) led by Ouroboros Capital. Mayo Clinic spinout. Engineered pigs as bio-incubators for human hepatocyte production at scale.
About
Cytotheryx is a Mayo Clinic spinout developing human hepatocytes (liver cells) produced at scale using genetically engineered pigs as bio-incubators. The company raised $60 million in Series A financing in January 2026 led by Ouroboros Capital, with GMP (Good Manufacturing Practice) manufacturing expansion underway to support both its acute liver failure support program and transplant-grade cell therapy pipeline.
Raised $381M IPO on Nasdaq (Feb 2026, EIKN). Proprietary RESOLFT super-resolution microscopy tracks single protein molecules in living cells. Creates new drug discovery data category.
About
Eikon Therapeutics is a drug discovery company that went public on Nasdaq in February 2026 (ticker: EIKN) with a $381 million IPO, armed with a proprietary RESOLFT super-resolution microscopy platform that tracks individual protein molecules in living cells in real time. Unlike computational drug discovery approaches that model proteins in isolation, Eikon's platform observes how proteins actually behave within the complex, dynamic environment of living cells — generating a new category of drug discovery data that no other method can produce.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.